Plus Therapeutics (PSTV) Provides Business Update on CNSide Diagnostics Subsidiary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
June 26, 2025 7:30 AM EDTU.S. commercial rollout of novel diagnostic platform to begin second half 2025
Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion
Management to host a conference call today at 9am ET
HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.... More
